2024 ASCO® Annual Meeting Insights Hub
Meeting coverage & Vumedi’s exclusive highlights, all in one place.
Playback speed
10 seconds
ASCO® 2024 Insights: "Roginolisib, an Oral, Highly Selective and Allosteric Modulator of PI3Kd for Uveal Melanoma and Advanced Cancers"
37 views
June 12, 2024
Chapters
Roginolisib's Role & Study Rationale
00:00
Phase I Trial Design & Demographics
03:02
Clinical Outcomes & Future Directions
05:31
Comments 0
Login to view comments.
Click here to Login